Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04533347 · ClinicalTrials.gov registry record · Phase 2
Tafenoquine in Patients With Mild to Moderate COVID-19
A Phase 2 study, sponsored by 60 Degrees Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 86
- Enrollment target
NCT04533347 is a Phase 2 study that has completed, run by 60 Degrees Pharmaceuticals. The registered enrollment target is 86 participants.
The verdict
NCT04533347, a Phase 2 study, has completed, sponsored by 60 Degrees Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 86 participants
- Enrollment target
Study Summary
A clinical study to assess the efficacy and safety of oral tafenoquine compared to placebo in patients with mild to moderate COVID 19 disease.
Interventions
- DRUG Placebo
- DRUG Tafenoquine Oral Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2021-02-19 |
| Est. Completion | 2022-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04533347
The ClinicalTrials.gov registry entry for NCT04533347 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is 60 Degrees Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04533347 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04533347 about?
NCT04533347 is a clinical study titled "Tafenoquine in Patients With Mild to Moderate COVID-19". A clinical study to assess the efficacy and safety of oral tafenoquine compared to placebo in patients with mild to moderate COVID 19 disease.
What is the current status of trial NCT04533347?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2021-02-19. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT04533347?
The interventions under investigation include: Placebo (DRUG), Tafenoquine Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT04533347?
This trial is sponsored by 60 Degrees Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.